Edwards Lifesciences (EW) Tops Q2 EPS by 8c; Lifts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Edwards Lifesciences Reports Second Quarter Results
July 28, 2015 4:01 PM EDTIRVINE, Calif., July 28, 2015 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today reported net income for the quarter ended June 30, 2015 of $112.7 million, or $1.02 per diluted share. Adjusted net income on a non-GAAP basis was $124.4 million, or $1.13 per diluted share, compared to $0.88 per diluted share in the prior year period. In the year ago period, GAAP net income was $5.09 per diluted share, which included a $750 million payment to Edwards from a litigation... More
